TNB Tech Minute: FDA Reverses Rejection of Another Rare-Disease Drug

Speaker 10:00

Many companies are struggling to scale their AI deployments or even move them past the pilot stage. Often the problem isn't technology, but organizational misalignment around goals, processes, and incentives. At the break, join Caroline Roach, a senior partner at IBM Consulting, to learn why.

Danny Lewis· Host0:14

[upbeat music] Here's your Morning TNB Tech Minute for Monday, June 22nd. I'm Danny Lewis for The Wall Street Journal. We exclusively report that biotech company ReGenxBio says the US Food and Drug Administration has agreed to reverse its rejection of an experimental gene therapy. The therapy targets Hunter syndrome, a rare fatal genetic disease that causes irreversible brain damage and cell death. The about face is the latest by the agency that's under new leadership and marks a broader retreat from demands that rare disease drug makers test their experimental medicines against placebos to make sure the drugs work. After filing an appeal, ReGenxBio says the FDA indicated it would drop demands for the new study. The FDA did not respond to a request for comment. Chevron has struck a 20-year agreement to sell electricity to Microsoft to power what could become one of the country's largest AI data centers. The oil company is working with energy company Julant to supply the West Texas data center with natural gas produced in the area. The companies didn't disclose a cost estimate for the project. The data center will have its own on-site power plant instead of being plugged into the Texas grid, but will connect to the grid at a later date to sell excess electricity into the power market. The deal cements Chevron's lead in the